What new Dupilumab data suggest about long-term immune control in allergic disease at Regeneron Pharmaceuticals
Ryerson Holding (NYSE: RYI) finalises Olympic Steel acquisition as North American metals consolidation accelerates
Read More 4 minute read Pharma Industry News MetaVia unveils synergistic liver disease data on DA-1241 and Efruxifermin at ADA 2025 MetaVia unveils ADA 2025 pre-clinical data showing DA-1241 and Efruxifermin combo improves MASH liver inflammation and fibrosis beyond monotherapies. byPallavi MadhirajuJune 21, 2025